Want to see GB:COIL full AI Analyst Report?
Roquefort Investments PLC (COIL) AI Stock Analysis
Roquefort Investments PLC
(LSE:COIL)
Weak financials with ongoing losses and cash burn dominate, reinforced by bearish technicals and poor valuation; oversold signals offer minor upside potential.
Roquefort Investments PLC (COIL) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 298.22K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 0.53
- Revenue Growth
- ―
- EPS Growth
- -204.28%
- Country
- UK
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Roquefort Investments PLC Business Overview & Revenue Model
Company Description
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Ro...
How the Company Makes Money
null
Roquefort Investments PLC Financial Statement Overview
Summary
Persistent losses, no revenue, and heavy cash burn outweigh balance sheet strengths like low debt and improving ROE, signaling high risk in pre-revenue biotech.
Income Statement
12Very NegativeBalance Sheet
65PositiveCash Flow
18Very NegativeRoquefort Investments PLC Peers Comparison
Overall Rating
GB:PRTC50Neutral
GB:FAB49Neutral
GB:SAR47Neutral
GB:AVCT43Neutral- GB:COIL39Underperform
GB:CIZ39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:PRTC | 50Neutral | GBP 287.84M | 160.04 | 0.14% | ― | -4.11% | -96.92% |
| GB:FAB | 49Neutral | GBP 7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% |
| GB:SAR | 47Neutral | GBP 24.95M | -4.19 | -284.01% | ― | ― | -105.65% |
| GB:AVCT | 43Neutral | GBP 294.51M | -6.44 | -1293.07% | ― | ― | ― |
| GB:COIL | 39Underperform | GBP 29.45M | -0.16 | -18.30% | ― | ― | -204.28% |
| GB:CIZ | 39Underperform | GBP 5.28M | -7.19 | 192.61% | ― | ― | 42.86% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:COIL | Roquefort Investments PLC | 6.90 | -8.85 | -56.19% | |
| GB:AVCT | Avacta Group plc | 58.70 | -12.80 | -17.90% | |
| GB:CIZ | Cizzle Biotechnology Holdings PLC | 1.15 | -0.50 | -30.30% | |
| GB:PRTC | PureTech Health | 119.40 | -9.00 | -7.01% | |
| GB:SAR | Sareum Holdings | 15.25 | 0.25 | 1.67% | |
| GB:FAB | Fusion Antibodies Plc | 6.00 | -6.75 | -52.94% |
Roquefort Investments PLC Corporate Events
Roquefort Therapeutics to buy AO-252 licence, raise £8.5m and move to AIM
PositiveRoquefort Therapeutics has agreed to acquire the exclusive worldwide licence to AO-252, a clinical-stage, orally administered, brain-penetrant small molecule inhibitor of TACC3 from Coiled Therapeutics Inc. The deal, valued at £31.875 million in...
Roquefort Therapeutics to Acquire Cancer Drug AO-252 and Shift Listing to AIM
PositiveRoquefort Therapeutics plans to acquire worldwide exclusive rights to AO-252, a TACC3-targeting oncology drug candidate from Coiled Therapeutics and A2A Pharmaceuticals, while completing an associated equity fundraise and preparing documentation for...
Roquefort Therapeutics Flags New Broker Research on Coiled and A2A Deal
PositiveRoquefort Therapeutics has announced that its broker, SP Angel Corporate Finance, has published a new research note analysing the company’s proposed transaction with clinical-stage oncology firm Coiled Therapeutics and AI-driven drug discovery...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 04, 2026